10x Genomics, Inc.
TXG Nasdaq· Laboratory Analytical Instruments
Last close · Oct 27, 2026
$78.02
KIRA · Stoqly’s AI analyst, in plain words
- 10x Genomics, Inc. had $643M of revenue in fiscal 2025, up 5.2% on the year before. Over five years, revenue changed +16.6% a year on average.
- Its operating margin was −9.5%, up 22.4 pts: of every 100 in sales, about −9 is left after running the business.
- 10x Genomics, Inc. lost $43.5M in fiscal 2025.
- Free cash flow was $130M in fiscal 2025, 20.2% of revenue.
Market cap
$10.1B
P/E
—
Revenue
$643M
Net income
−$43.5M
Free cash flow
$130M
Operating margin
−9.5%
10x Genomics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+5.2%
Yes. Sales grew 5.2% last year.
Does it make a profit?
−6.8%
No. It lost money last year.
Does profit turn into cash?
20.2%
Yes. 20.2% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What 10x Genomics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 13, 2026
- Legal name
- 10x Genomics, Inc.
- CIK
- 0001770787
10x Genomics, Inc. · TXG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $490M | $516M | $619M | $611M | $643M |
| Revenue growth | 64.1% | 5.3% | 19.8% | −1.3% | 5.2% |
| Gross margin | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% |
| Operating margin | −10.7% | −32.5% | −42.9% | −31.9% | −9.5% |
| Net income | −$58.2M | −$166M | −$255M | −$183M | −$43.5M |
| Net margin | −11.9% | −32.1% | −41.2% | −29.9% | −6.8% |
| Diluted EPS | −$0.53 | −$1.46 | −$2.18 | −$1.52 | −$0.35 |
| Cash | |||||
| Cash from operations | −$21.4M | −$33.6M | −$15.2M | $6.7M | $136M |
| Capital expenditure | $101M | $132M | $48.6M | $12.4M | $5.9M |
| Free cash flow | −$123M | −$165M | −$63.8M | −$5.7M | $130M |
| FCF margin | −25.0% | −32.0% | −10.3% | −0.9% | 20.2% |
| Share count change | 9.1% | 3.2% | 2.9% | 2.8% | 3.6% |
| Debt and strength | |||||
| Cash and short-term investments | $587M | $430M | $389M | $393M | $523M |
| Shareholders' equity | $818M | $806M | $741M | $710M | $796M |
| Current ratio | 6.8x | 4.8x | 4.7x | 5.0x | 4.5x |
| Interest coverage | −60.3x | −352.8x | −8,040.3x | −48,639.8x | — |
| Returns and quality | |||||
| Return on equity | −7.5% | −20.5% | −33.0% | −25.2% | −5.8% |
| Return on tangible equity | −7.4% | −21.3% | −35.4% | −26.5% | −6.0% |
| Piotroski F-score | 5 | 2 | 2 | 6 | 4 |
| Altman Z'' | 5.3 | 2.6 | 0.5 | 0.3 | 1.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$16.9M
6 insiders
Of sales under plans
57%
$9.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
10x Genomics, Inc. · TXG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $78.02 a share, the company is worth $10.1B.
Source: SEC EDGAR XBRL filings (CIK 0001770787). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.